Advertisement
Advertisement
ADMA
ADMA Biologics, Inc.
9.90
USDSponsored
-0.16
-1.59%
Aug 07, 15:59 UTC -4
Closed
After-Market
9.89
-0.01
-0.05%
ADMA Earnings Reports
Positive Surprise Ratio
ADMA beat 19 of 43 last estimates.
44%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$147.70M
/$0.21
Implied change from Q2 26 (Revenue/ EPS)
+18.73%
/+31.25%
Implied change from Q3 25 (Revenue/ EPS)
+10.04%
/+40.00%
ADMA Biologics, Inc. earnings per share and revenue
On Aug 05, 2026, ADMA reported earnings of 0.16 USD per share (EPS) for Q2 26, missing the estimate of 0.18 USD, resulting in a -12.85% surprise. Revenue reached 124.40 million, compared to an expected 134.29 million, with a -7.37% difference. The market reacted with a +8.64% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.21 USD, with revenue projected to reach 147.70 million USD, implying an increase of 31.25% EPS, and increase of 18.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
What were ADMA Biologics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, ADMA Biologics, Inc. reported EPS of $0.16, missing estimates by -12.85%, and revenue of $124.40M, -7.37% below expectations.
How did the market react to ADMA Biologics, Inc.'s Q2 2026 earnings?
The stock price moved up 8.64%, changed from $9.26 before the earnings release to $10.06 the day after.
When is ADMA Biologics, Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for ADMA Biologics, Inc.'s next earnings report?
Based on 4
analysts, ADMA Biologics, Inc. is expected to report EPS of $0.21 and revenue of $147.70M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement